Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internat…
Biotechnology
US, Novato [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Ultragenyx Pharmaceutical Inc. (RARE) to it's peer group, including competitors as well as it's industry.
All monetary values in mil. except volume - volume is in thousands.
Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biotechnology Average | - - | - - | - - | 13,382.43 | 894.68 | 137.45 | 358.64 | 14.73 | 0.00 | 24.3930 | -0.87 | -0.9106 | -21.3735 | -0.08 | -0.07 | 7.1836 | - - | ||
Maximum | - - | - - | - - | 444,129.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.02 | 1,336.3467 | 6.70 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
Minimum | - - | - - | - - | 0.00 | 0.00 | -6,783.00 | -56,335.00 | -2,077.00 | 0.00 | -164.8536 | -57.22 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0007 | - - | ||
Apellis Pharmaceuticals, Inc. APLS | 27.75 | 0.26 0.95% | 1,488 vs. 2,868 | 3,451.00 | 172.00 | -66.00 | -133.00 | -2,903.00 | -0.5400 | -27.6326 | 0.0000 | 0.8802 | -0.3855 | -0.2491 | -0.0798 | 2.7985 | 124.00 | ||
United Therapeutics Corporation UTHR | 367.36 | 3.03 0.83% | 201 vs. 363 | 16,400.00 | 677.00 | 306.00 | 338.00 | 6,333.00 | 6.5200 | 8.7477 | 0.0000 | 0.8924 | 0.4524 | 0.0574 | 0.0472 | 3.5035 | 44.00 | ||
Incyte Corporation INCY | 70.39 | -0.66 -0.93% | 2,109 vs. 2,066 | 13,560.00 | 880.00 | 169.00 | 209.00 | 329.00 | 0.7600 | 18.7480 | 0.0000 | 0.9308 | 0.1925 | 0.0314 | 0.0238 | 3.2913 | 192.00 | ||
Alnylam Pharmaceuticals, Inc. ALNY | 246.80 | -1.99 -0.80% | 676 vs. 859 | 31,832.00 | 494.00 | -65.00 | -94.00 | -7,075.00 | -0.5200 | -73.3326 | 0.0000 | 0.8665 | -0.1334 | 0.3007 | -0.0172 | 2.8593 | 128.00 | ||
Ultragenyx Pharmaceutical Inc. RARE | 46.02 | -0.38 -0.82% | 509 vs. 723 | 4,249.00 | 108.00 | -170.00 | -203.00 | -3,558.00 | -2.0300 | -5.7986 | 0.0000 | 0.7576 | -1.5683 | -1.2169 | -0.1306 | 2.1127 | 92.00 | ||
Revolution Medicines, Inc. RVMD | 56.78 | -0.29 -0.51% | 864 vs. 1,174 | 9,551.00 | 0.00 | -116.00 | -163.00 | -1,253.00 | -0.7000 | -11.2467 | 0.0000 | 0.0000 | 0.0000 | -0.0672 | -0.0608 | 18.1763 | 168.00 |
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.